Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
See detailL’Antiquité et le Moyen Âge
Jadoulle, Jean-Louis ULg; Hasquin, Hervé

Book (2008)

Detailed reference viewed: 20 (3 ULg)
Full Text
See detailAntiquité tardive et christianisme africains dans l'Africa romana : un bilan historiographique
Fialon, Sabine ULg

in Ruggeri, Paola (Ed.) L’Africa romana XX. Momenti di continuita e rottura : bilancio di 30 anni di convegni de l’Africa romana (2016)

Detailed reference viewed: 50 (3 ULg)
Full Text
Peer Reviewed
See detailAntireflective subwavelength patterning of IR optics
Vandormael, Denis; Habraken, Serge ULg; Loicq, Jerôme ULg et al

in Proceedings of SPIE (2006), 6395

Thermal infrared (IR) lenses require efficient anti-reflection coating. Moth-eye (or egg-box) 2D subwavelength gratings have demonstrated their ability to reach a very high transmission for a wide ... [more ▼]

Thermal infrared (IR) lenses require efficient anti-reflection coating. Moth-eye (or egg-box) 2D subwavelength gratings have demonstrated their ability to reach a very high transmission for a wide wavelength and angular range. The use in thermal IR is simplified by the lower resolution for lithographic technology, compared to visible waveband. However, deeper structures must be engraved and lithography must be adapted to IR materials. In order to be cost-effective, the patterning must be produced by replication techniques, such as embossing. Our laboratory is now experimenting hot embossing of moth-eye patterns in chalcogenide substrates. In this paper, theoretical analysis, micro-lithographic technology and manufacturing processes are detailed. [less ▲]

Detailed reference viewed: 69 (6 ULg)
Full Text
Peer Reviewed
See detailAntiresorptive Drugs Beyond Bisphosphonates and Selective Oestrogen Receptor Modulators for the Management of Postmenopausal Osteoporosis.
Reginster, Jean-Yves ULg; Neuprez, A.; Beaudart, Charlotte ULg et al

in Drugs & aging (2014), 31

Osteoporotic fractures are a major cause of morbidity in the elderly population. Since postmenopausal osteoporosis is related to an increase in osteoclastic activity at the time of menopause, inhibitors ... [more ▼]

Osteoporotic fractures are a major cause of morbidity in the elderly population. Since postmenopausal osteoporosis is related to an increase in osteoclastic activity at the time of menopause, inhibitors of bone resorption have genuinely been considered an adequate strategy for prevention and treatment of osteoporosis. Bisphosphonates and selective oestrogen receptor modulators are widely prescribed to treat osteoporosis. However, other antiresorptive drugs have been developed for the management of osteoporosis, with the objective of providing a substantial reduction in osteoporotic fractures at all skeletal sites, combined with an acceptable long-term skeletal and systemic safety profile. Denosumab, a human monoclonal antibody to receptor activator for nuclear factor kappa B ligand, has shown efficacy against vertebral, nonvertebral and hip fractures. Its administration every 6 months as a subcutaneous formulation might significantly influence compliance and persistence to therapy. Additional results regarding long-term skeletal safety (i.e. osteonecrosis of the jaw and atypical diaphyseal femoral fracture) are needed. Odanacatib, a selective cathepsin K inhibitor, is a promising new approach to the inhibition of osteoclastic resorption, with the potential to uncouple bone formation from bone resorption. Results regarding its anti-fracture efficacy are expected in the coming months. [less ▲]

Detailed reference viewed: 32 (10 ULg)
Full Text
Peer Reviewed
See detailAntisense galectin-3 alters thymidine incorporation in human MDA-MB435 breast cancer cells
van den Brûle, Frédéric; Bellahcene, Akeila ULg; Jackers, Pascale ULg et al

in International Journal of Oncology (1997), 11(2), 261-264

Detailed reference viewed: 49 (27 ULg)
Full Text
Peer Reviewed
See detailAntisickling properties of divanilloylquinic acids isolated from Fagara zanthoxyloides Lam. (Rutaceae).
Ouattara, Badiore; Jansen, Olivia ULg; Angenot, Luc ULg et al

in Phytomedicine : International Journal of Phytotherapy and Phytopharmacology (2009), 16(2-3), 125-129

Fagara zanthoxyloides Lam. (syn. Zanthoxylum zanthoxyloides) (Rutaceae) is the most cited Fagara species for the treatment and the prevention of sickle cell disease crisis. Sickle cell anemia (SCA) is a ... [more ▼]

Fagara zanthoxyloides Lam. (syn. Zanthoxylum zanthoxyloides) (Rutaceae) is the most cited Fagara species for the treatment and the prevention of sickle cell disease crisis. Sickle cell anemia (SCA) is a public health problem in many countries particularly in Africa. The present study was designed to evaluate the antisickling properties of three isomeric divanilloylquinic acids (3,4-O-divanilloylquinic acid or burkinabin A; 3,5-O-divanilloylquinic acid or burkinabin B and 4,5-O-divanilloylquinic acid or burkinabin C) identified previously by LC/MS/NMR analysis in the root bark of F. zanthoxyloides [Ouattara et al., 2004. LC/MS/NMR analysis of isomeric divanilloylquinic acids from the root bark of Fagara zanthoxyloides Lam. Phytochemistry 65, 1145-1151]. The three isomers showed interesting antisickling properties which increased from burkinabins A to C. [less ▲]

Detailed reference viewed: 199 (24 ULg)
See detailL’antithèse de la psychopathologie : à propos d’un inexistant
Englebert, Jérôme ULg

Scientific conference (2014, December 12)

Detailed reference viewed: 18 (3 ULg)
Full Text
Peer Reviewed
See detailAntithrombin III in the therapy of severe sepsis
Lamy, Maurice ULg; Eisele, B.

in Biomedical Progress (1996), 9

Detailed reference viewed: 9 (0 ULg)
Full Text
Peer Reviewed
See detailAntithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome : a study from the French Society of Bone Marrow Transplantation and Cellular Therapy
Duléry, Rémy; Mohty, Mohamad; Duhamel, Alain et al

in Biology of Blood & Marrow Transplantation (2014), 20

We investigated the impact of rabbit antithymocyte globulins (ATG) on patient outcomes after allogeneic stem cell transplantation (allo-SCT) for progressive myelodysplastic syndrome (MDS). Of the 242 ... [more ▼]

We investigated the impact of rabbit antithymocyte globulins (ATG) on patient outcomes after allogeneic stem cell transplantation (allo-SCT) for progressive myelodysplastic syndrome (MDS). Of the 242 consecutive patients who underwent allo-SCT for progressive MDS between October 1999 and December 2009, 93 received ATG (ATG group) at the median dose of 5 mg/kg, whereas 149 patients did not (no-ATG group). Donors were sibling (n ¼ 153) or HLA-matched unrelated (n ¼ 89). Patients received blood (n ¼ 90) or marrow (n ¼ 152) grafts after either myeloablative (n ¼ 109) or reduced-intensity (n ¼ 133) conditioning. Three-year overall and event-free survival, nonrelapse mortality, relapse, and chronic graft-versus-host disease (GVHD) development were not significantly different between the 2 groups. In contrast, acute grade II to IV GVHD occurred more often in the no-ATG group (55% of the patients) than in the ATG group (27%, P < .0001). Similar results were observed with acute grade III to IV GVHD (28% and 14% in the no-ATG group and ATG group, respectively; P ¼ .009). In multivariate analysis, after adjustment with propensity score, the absence of ATG was the strongest parameter associated with an increased risk of acute grade II to IV GVHD (hazard ratio, 2.13; 95% confidence interval, 1.35 to 3.37; P ¼.001]. ATG had no impact on overall and event-free survival or cumulative incidence of the relapse. In conclusion, the addition of ATG to allo-SCT conditioning did not increase the incidence of relapse of patients with progressive MDS. The incidence of acute GVHD was decreased without compromising outcomes. [less ▲]

Detailed reference viewed: 51 (3 ULg)
See detailAntitoxic defence systems and biochemistry variations in two gammarids and influence of the Acanthocephalan Polymorphus minutus.
Gismondi, Eric ULg; Sroda, Sophie; Beisel, Jean-Nicolas et al

Conference (2009, September)

Detailed reference viewed: 18 (1 ULg)
Full Text
Peer Reviewed
See detailThe Antitrust and Intellectual Property Intersection in European Union Law
Petit, Nicolas ULg

in Blair, Roger; Sokol, Danie (Eds.) Roger D. Blair & D. Daniel Sokol (in press)

In European legal scholarship, many articles discuss the equilibrium reached in the case-law of the Court of Justice of the European Union (“CJEU”) when the EU antitrust prohibitions apply to, and ... [more ▼]

In European legal scholarship, many articles discuss the equilibrium reached in the case-law of the Court of Justice of the European Union (“CJEU”) when the EU antitrust prohibitions apply to, and restrain, the free and ordinary use of intellectual property rights (“IPRs”). We call this the antitrust-IP intersection. The most interesting feature of this literature is perhaps the common assumption that a unifying substantive perspective, vision or theory on IPR underpins the intersection point reached by the antitrust case-law. Whilst the theory of “absolutism” can be quickly disposed of, several other theories like inherency, exceptionalism or complementarity have been described as the lynchpin of the antitrust-IP intersection. Our paper offers a different reading of the case-law. It submits that the antitrust-IP intersection does not rest on any unitary theory which, in turn, bespeaks the Court’s vision of the social function of IPRs. Instead, the main feature of the CJEU case-law is that a specific methodology is applied to antitrust cases with IPR ramifications. The CJEU deals with most of such cases under a rule-based approach, instead of a standard-based approach. By rule-based approach, we refer to the ex ante setting of structured tests of liability, by opposition to ex post case-by-case resolution on grounds of a pre-determined, general standard (e.g., reasonableness, competition on the merits, efficiency, fairness, equity, etc.). As will be seen below, this approach has many virtues, not least in terms of legal certainty. But it also has a major qualification. Whilst the Court has consistently formulated rules of liability and justifiability at the antitrust and IP intersection, it has at the same time often embedded abstract standards within those rules. The implications of this mixed approach are unclear. [less ▲]

Detailed reference viewed: 101 (5 ULg)
Full Text
See detailAntitrust and The challenge of policing « moligopolists »
Petit, Nicolas ULg

Conference (2015, May 29)

Detailed reference viewed: 88 (5 ULg)
Full Text
See detailAntitrust Damages in EU Law and Policy : Jurisdiction Issues and Applicable Law: Brussels I, Rome I and II
Francq, Stéphanie; Wautelet, Patrick ULg

Conference (2013, November)

This presentation (co-authored with Prof. Stéphanie Francq - UCLouvain) gives an overview of the main issues arising in relation to the private enforcement of competition law within the EU, from a private ... [more ▼]

This presentation (co-authored with Prof. Stéphanie Francq - UCLouvain) gives an overview of the main issues arising in relation to the private enforcement of competition law within the EU, from a private international law perspective. The focus is on the determination of the jurisdiction and of the applicable law [less ▲]

Detailed reference viewed: 135 (3 ULg)
Full Text
Peer Reviewed
See detailThe antitrypanosomal drug melarsoprol competitively inhibits thiamin uptake in mouse neuroblastoma cells
Szyniarowski, Piotr; Bettendorff, Lucien ULg; Schweingruber, M. E.

in Cell Biology and Toxicology (2006), 22(3), 183-187

Melarsoprol is the main drug used for the treatment of late-stage sleeping sickness, although it causes severe side-effects such as encephalopathy and polyneuropathy leading to death in some patients ... [more ▼]

Melarsoprol is the main drug used for the treatment of late-stage sleeping sickness, although it causes severe side-effects such as encephalopathy and polyneuropathy leading to death in some patients. Recent data suggest that melarsoprol and its active metabolite melarsenoxide interfere with thiamin transport and metabolism in E. coli and yeast, but there are no data concerning their possible effects on thiamin metabolism in mammalian cells. We tested both drugs on thiamin transport in cultured mouse neuroblastoma cells using C-14-labeled thiamin. Melarsoprol, competitively inhibits high-affinity thiamin transport in mouse neuroblastoma cells with a K-i of 44 mu mol/L. However, the active compound melarsenoxide has no inhibitory effect. This suggests that the side effects of melarsoprol treatment are unlikely to be due to inhibition of thiamin transport by melarsenoxide, its main metabolite in the brain. [less ▲]

Detailed reference viewed: 37 (3 ULg)
Full Text
Peer Reviewed
See detailAntitumor and anti-angiogenic effects of aplidin in the 5T33MM model, syngeneic model of multiple myeloma
Caers, Jo ULg; De Raeve, Hendrik; Lepage, Doreen et al

in British Journal of Cancer (2008), 98(12), 1966-74

Detailed reference viewed: 24 (0 ULg)